Re: NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Casella
R
R
Lehmann
K
K
Gasser
T C
TC
D014408:Biomarkers, Tumor / Q000097:blood*; D003362:Cost-Benefit Analysis; D006801:Humans; D009687:Nuclear Proteins / Q000097:blood*; D010865:Pilot Projects; D012307:Risk Factors; D012680:Sensitivity and Specificity; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000175:diagnosis*
D014408:Biomarkers, Tumor; D009687:Nuclear Proteins; C100379:nuclear matrix protein 22